Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year High – Should You Buy?

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) hit a new 52-week high during trading on Tuesday . The stock traded as high as $82.26 and last traded at $81.40, with a volume of 100975 shares trading hands. The stock had previously closed at $80.78.

Analyst Upgrades and Downgrades

HALO has been the topic of several analyst reports. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $81.60.

Halozyme Therapeutics Stock Performance

The firm has a market capitalization of $9.71 billion, a PE ratio of 29.45, a price-to-earnings-growth ratio of 0.33 and a beta of 0.84. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The business’s 50 day simple moving average is $69.69 and its two-hundred day simple moving average is $69.58.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $55,088,215. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 72,179 shares of company stock valued at $5,052,400. 2.50% of the stock is owned by company insiders.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Clark Capital Management Group Inc. increased its stake in shares of Halozyme Therapeutics by 14.4% in the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock worth $14,885,000 after purchasing an additional 25,582 shares in the last quarter. Allworth Financial LP lifted its position in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after purchasing an additional 30,331 shares in the last quarter. Element Squared LLC bought a new stake in Halozyme Therapeutics during the fourth quarter valued at about $1,193,000. Dimensional Fund Advisors LP grew its holdings in Halozyme Therapeutics by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after purchasing an additional 63,699 shares during the period. Finally, CWA Asset Management Group LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth about $907,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.